The effects of bolus infusion versus continuous injection of doxorubicin in children with ALL

The comparison of bolus infusion versus continuous injection of doxorubicin in children with ALL

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180209038673N7

Enrollment

Registered

2024-01-02

Start date

2023-12-20

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphoblastic leukemia. Acute lymphoblastic leukemia not having achieved remission

Interventions

Intervention 1: Intervention group: Group A patients receive adriamycin through bolus injection. Before the intervention and 6 months after the intervention, the patients undergo echocardiography. The

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: Normal echocardiography, Written consent from parents, patients under 18 years of age, patients with ALL who usd doxorubicin in their drug regimen

Exclusion criteria

Exclusion criteria: Previous history of chemotherapy or radiation therapy Diagnosis of congenital heart disease Diagnosis of heart failure Diagnosis of kidney failure

Design outcomes

Primary

Measure	Time frame
Cardiotoxicity effect. Timepoint: 6 months after treatment. Method of measurement: Echocardiography.	—

Secondary

Measure	Time frame
WBC measurement. Timepoint: 6 months after therapy. Method of measurement: CBC instrument.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Elnaz Sheikhpour

Yazd University of Medical Sciences

r.sheikhpour@yahoo.com+98 35 3822 4000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026